
Caixa launches latest biotech fund
Spanish venture investor Caixa Capital Risc has launched its second biotech fund with a target of €35m.
Established in partnership with the Ministry of Economy and Competitiveness through the Centre for Technological and Industrial Development (CDTI), Caixa Innvierte BioMed II will back life sciences companies in Spain.
Spanish VC player Ysios Capital also launched its second biotech fund yesterday, with a €100m target. According to research by the Spanish Association of Biotech Companies, scientific research amounts to 7.15% of GDP.
Investments
The fund will commit to series-A and series-B funding rounds for Spanish firms in the life sciences sector. The minimum equity ticket is €500,000, with maximum investment capped at €4.5m. Average investment size is expected to stand at around €2.5m.
Investors
The majority of LP commitments will come from Criteria CaixaCorp and the CDTI. VidaCaixa, the Catalan Institute of Finances and Laboratorios LETI will also contribute to the fund.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds